These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
552 related items for PubMed ID: 15452361
1. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Yu GL, Wei EQ, Zhang SH, Xu HM, Chu LS, Zhang WP, Zhang Q, Chen Z, Mei RH, Zhao MH. Pharmacology; 2005 Jan; 73(1):31-40. PubMed ID: 15452361 [Abstract] [Full Text] [Related]
2. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. Zhao R, Shi WZ, Zhang YM, Fang SH, Wei EQ. J Pharm Pharmacol; 2011 Apr; 63(4):550-7. PubMed ID: 21401607 [Abstract] [Full Text] [Related]
3. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Shi QJ, Wang H, Liu ZX, Fang SH, Song XM, Lu YB, Zhang WP, Sa XY, Ying HZ, Wei EQ. Neuroscience; 2015 Apr 16; 291():53-69. PubMed ID: 25681271 [Abstract] [Full Text] [Related]
5. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Zhang WP, Wei EQ, Mei RH, Zhu CY, Zhao MH. Acta Pharmacol Sin; 2002 Oct 26; 23(10):871-7. PubMed ID: 12370090 [Abstract] [Full Text] [Related]
6. Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice. Chu LS, Wei EQ, Yu GL, Fang SH, Zhou Y, Wang ML, Zhang WP. Acta Pharmacol Sin; 2006 Mar 26; 27(3):282-8. PubMed ID: 16490162 [Abstract] [Full Text] [Related]
7. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Yu GL, Wei EQ, Wang ML, Zhang WP, Zhang SH, Weng JQ, Chu LS, Fang SH, Zhou Y, Chen Z, Zhang Q, Zhang LH. Brain Res; 2005 Aug 16; 1053(1-2):116-25. PubMed ID: 16051204 [Abstract] [Full Text] [Related]
8. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Shi QJ, Xiao L, Zhao B, Zhang XY, Wang XR, Xu DM, Yu SY, Fang SH, Lu YB, Zhang WP, Sa XY, Wei EQ. Brain Res; 2012 Nov 12; 1484():57-67. PubMed ID: 23000196 [Abstract] [Full Text] [Related]
9. [Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice]. Zeng LH, Zhang WP, Wang RD, Wang PL, Wei EQ. Yao Xue Xue Bao; 2001 Feb 12; 36(2):148-50. PubMed ID: 12579886 [Abstract] [Full Text] [Related]
10. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Fang SH, Wei EQ, Zhou Y, Wang ML, Zhang WP, Yu GL, Chu LS, Chen Z. Neuroscience; 2006 Jul 07; 140(3):969-79. PubMed ID: 16650938 [Abstract] [Full Text] [Related]
11. Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury. Qian XD, Wei EQ, Zhang L, Sheng WW, Wang ML, Zhang WP, Chen Z. Eur J Pharmacol; 2006 Nov 07; 549(1-3):35-40. PubMed ID: 16973153 [Abstract] [Full Text] [Related]
12. [An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia]. Wei EQ, Zhu CY, Xu QQ, Yu YP, Zhu YF, Zheng MZ. Sheng Li Xue Bao; 2003 Dec 25; 55(6):742-7. PubMed ID: 14695495 [Abstract] [Full Text] [Related]
13. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. Saad MA, Abdelsalam RM, Kenawy SA, Attia AS. Neurochem Res; 2015 Jan 25; 40(1):139-50. PubMed ID: 25403620 [Abstract] [Full Text] [Related]
14. Cysteinyl leukotriene receptors CysLT1 and CysLT2 are upregulated in acute neuronal injury after focal cerebral ischemia in mice. Zhang YJ, Zhang L, Ye YL, Fang SH, Zhou Y, Zhang WP, Lu YB, Wei EQ. Acta Pharmacol Sin; 2006 Dec 25; 27(12):1553-60. PubMed ID: 17112408 [Abstract] [Full Text] [Related]
15. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury. Biber N, Toklu HZ, Solakoglu S, Gultomruk M, Hakan T, Berkman Z, Dulger FG. Brain Inj; 2009 Jun 25; 23(6):577-84. PubMed ID: 19484631 [Abstract] [Full Text] [Related]
16. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier. Zhou L, Sun X, Shi Y, Liu J, Luan G, Yang Y. Inflammopharmacology; 2019 Oct 25; 27(5):933-940. PubMed ID: 31313075 [Abstract] [Full Text] [Related]
17. Therapeutic neuroprotective effects of XQ-1H in a rat model of permanent focal cerebral ischemia. Yang Q, Fang W, Lv P, Geng X, Li Y, Sha L. Pharmacology; 2012 Oct 25; 89(1-2):1-6. PubMed ID: 22178991 [Abstract] [Full Text] [Related]
18. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Xu J, Culman J, Blume A, Brecht S, Gohlke P. Stroke; 2003 May 25; 34(5):1287-92. PubMed ID: 12677021 [Abstract] [Full Text] [Related]
19. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats. Thiyagarajan M, Kaul CL, Sharma SS. Br J Pharmacol; 2004 Jul 25; 142(5):899-911. PubMed ID: 15197101 [Abstract] [Full Text] [Related]
20. Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia. Shichinohe H, Kuroda S, Yasuda H, Ishikawa T, Iwai M, Horiuchi M, Iwasaki Y. Brain Res; 2004 Dec 17; 1029(2):200-6. PubMed ID: 15542075 [Abstract] [Full Text] [Related] Page: [Next] [New Search]